Elizabeth M. Burton

12.5k total citations
84 papers, 574 citations indexed

About

Elizabeth M. Burton is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Elizabeth M. Burton has authored 84 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 24 papers in Molecular Biology and 24 papers in Genetics. Recurrent topics in Elizabeth M. Burton's work include Cancer Immunotherapy and Biomarkers (24 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Chronic Myeloid Leukemia Treatments (21 papers). Elizabeth M. Burton is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Chronic Myeloid Leukemia Treatments (21 papers). Elizabeth M. Burton collaborates with scholars based in United States, Australia and Netherlands. Elizabeth M. Burton's co-authors include Michael A. Davies, Sapna P. Patel, Jennifer A. Wargo, Hussein Tawbi, Jennifer L. McQuade, Rodabe N. Amaria, Jörge E. Cortes, Hagop M. Kantarjian, Michael K. Wong and Elias Jabbour and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Immunity.

In The Last Decade

Elizabeth M. Burton

73 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elizabeth M. Burton United States 14 292 169 114 112 96 84 574
Sherif Rezk United States 14 388 1.3× 151 0.9× 63 0.6× 132 1.2× 57 0.6× 41 753
John Galbincea United States 10 361 1.2× 293 1.7× 63 0.6× 66 0.6× 106 1.1× 13 636
Shinichi Makita Japan 16 403 1.4× 125 0.7× 114 1.0× 143 1.3× 49 0.5× 78 719
Christophe Passot France 11 116 0.4× 92 0.5× 93 0.8× 172 1.5× 98 1.0× 28 514
Lara Mussolin Italy 20 337 1.2× 409 2.4× 109 1.0× 240 2.1× 145 1.5× 73 1.2k
C. Papadimitriou Greece 15 281 1.0× 82 0.5× 80 0.7× 95 0.8× 137 1.4× 30 569
Jochen Casper Germany 13 145 0.5× 241 1.4× 85 0.7× 75 0.7× 86 0.9× 39 701
Flora N. Kontopidou Greece 17 216 0.7× 86 0.5× 255 2.2× 112 1.0× 64 0.7× 37 615
Martin Dreyling Germany 13 344 1.2× 89 0.5× 226 2.0× 84 0.8× 77 0.8× 28 622
Valentina Gianfelici Italy 15 168 0.6× 243 1.4× 133 1.2× 113 1.0× 71 0.7× 29 736

Countries citing papers authored by Elizabeth M. Burton

Since Specialization
Citations

This map shows the geographic impact of Elizabeth M. Burton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth M. Burton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth M. Burton more than expected).

Fields of papers citing papers by Elizabeth M. Burton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth M. Burton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth M. Burton. The network helps show where Elizabeth M. Burton may publish in the future.

Co-authorship network of co-authors of Elizabeth M. Burton

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth M. Burton. A scholar is included among the top collaborators of Elizabeth M. Burton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth M. Burton. Elizabeth M. Burton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guerrieri, Renato, Grant M. Fischer, Barbara Knighton, et al.. (2025). Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade. Scientific Reports. 15(1). 34352–34352.
2.
Levy, Erma, Justin Rains, Elizabeth Sirmans, et al.. (2024). The DIET study: A randomized controlled trial of a high fiber diet intervention (HFDI) in patients (pts) with melanoma receiving immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 42(16_suppl). 9558–9558. 2 indexed citations
3.
4.
Burton, Elizabeth M., Ashley Cimino‐Mathews, Tricia R. Cottrell, et al.. (2024). 1943P Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort. Annals of Oncology. 35. S1127–S1128.
5.
Keith, Scott W., et al.. (2024). Neoadjuvant chemotherapy versus primary surgery in patients with stage III/IV endometrial cancer: A National Cancer Database study.. Journal of Clinical Oncology. 42(16_suppl). 5603–5603. 1 indexed citations
6.
Burton, Elizabeth M., Khalida Wani, Denái R. Milton, et al.. (2024). Biomarker analysis and updated clinical outcomes: Neoadjuvant systemic treatment (NST) with nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma.. Journal of Clinical Oncology. 42(16_suppl). 9587–9587.
7.
8.
Schilder, Russell J., Mark S. Shahin, Mitchell I. Edelson, et al.. (2023). OATH trial: A phase II clinical trial evaluating the combination of onapristone with anastrozole for women with hormone receptor positive endometrial cancer—Preliminary results.. Journal of Clinical Oncology. 41(16_suppl). 5601–5601. 2 indexed citations
9.
Burton, Elizabeth M., Lauren Simpson, Víctor G. Prieto, et al.. (2023). Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9583–9583. 1 indexed citations
10.
Burton, Elizabeth M., Denái R. Milton, Isabella C. Glitza, et al.. (2023). 1085O Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM). Annals of Oncology. 34. S652–S653. 1 indexed citations
11.
Glitza, Isabella C., S. Phillips, Roland L. Bassett, et al.. (2023). 1082O Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD). Annals of Oncology. 34. S652–S652. 2 indexed citations
12.
Phillips, Suzanne, Elizabeth M. Burton, Firas Kreidieh, et al.. (2023). Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).. Journal of Clinical Oncology. 41(16_suppl). TPS9605–TPS9605. 5 indexed citations
13.
Burton, Elizabeth M., Rodabe N. Amaria, Tina Cascone, et al.. (2022). Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021. Journal of Translational Medicine. 20(1). 271–271. 6 indexed citations
14.
Tawbi, Hussein A., Tu My To, Karen Bartley, et al.. (2021). Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real‐world study. Cancer Medicine. 11(1). 139–150. 8 indexed citations
15.
Burton, Elizabeth M., Rodabe N. Amaria, Isabella Claudia Glitza, et al.. (2021). Phase II Study of TRIplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in patients (pts) with PD-1 naïve or refractory BRAF-mutated metastatic melanoma (MM) with or without active brain metastases.. Journal of Clinical Oncology. 39(15_suppl). 9520–9520. 16 indexed citations
16.
Keung, Emily Z., Nadim J. Ajami, Sheila Duncan, et al.. (2021). 191P Fecal microbiome in soft-tissue sarcoma (STS) patients treated with neoadjuvant immune checkpoint blockade (ICB). Annals of Oncology. 32. S1464–S1464. 1 indexed citations
17.
Smith, Harriet O., Clifford Qualls, Tao Wang, et al.. (2012). The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma. Molecular Oncology. 7(1). 41–54. 51 indexed citations
18.
Naqvi, Kiran, Hagop M. Kantarjian, Alfonso Quintás‐Cardama, et al.. (2010). Characteristics and Outcome of Chronic Myeloid Leukemia (CML) Patients with E255K and E255V BCR-ABL Kinase Domain Mutations.. Blood. 116(21). 1226–1226. 1 indexed citations
19.
Burton, Elizabeth M.. (1967). The Georgians at Home. 2 indexed citations
20.
Burton, Elizabeth M., et al.. (1962). The Jacobeans at home. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sherif Rezk Breakdown of academic impact, for papers by John Galbincea Breakdown of academic impact, for papers by Shinichi Makita Breakdown of academic impact, for papers by Christophe Passot Breakdown of academic impact, for papers by Lara Mussolin Breakdown of academic impact, for papers by C. Papadimitriou Breakdown of academic impact, for papers by Jochen Casper Breakdown of academic impact, for papers by Flora N. Kontopidou Breakdown of academic impact, for papers by Martin Dreyling Breakdown of academic impact, for papers by Valentina Gianfelici
Rankless by CCL
2026